Ki-67 immunocytochemistry in liquid based cervical cytology: Useful as an adjunctive tool?

Journal of Clinical Pathology

Volumn 56, Issue 9, 2003, Pages 681-686

  Sahebali, S ^a   Depuydt, C E ^b   Segers, K ^b   Vereecken, A J ^b   Van Marck, E ^a   Bogers, J J ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b Laboratory for Clinical Pathology (Labo Lokeren Campus RIATOL)   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; KI 67 ANTIGEN; VIRUS DNA;

AREA UNDER THE CURVE; ARTICLE; CELL COUNT; CONTROLLED STUDY; CYTODIAGNOSIS; CYTOLOGY; DIAGNOSTIC ACCURACY; DISEASE MARKER; DNA DETERMINATION; FEMALE; HIGH RISK POPULATION; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOCYTOCHEMISTRY; LIQUID; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; SCREENING TEST; SQUAMOUS CELL; UTERINE CERVIX CARCINOMA IN SITU; VIRUS DIAGNOSIS; VIRUS INFECTION;

BIOLOGICAL MARKERS; DNA, VIRAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL DISEASES; VAGINAL SMEARS;

EID: 0042261942     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.56.9.681     Document Type: Article

References (39)

1. Ho GY, Burk RD, Klein S, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995;87:1365-71.
2. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19.
3. Bosch FX, Lorincz A, Munoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-65.
4. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) study group. J Natl Cancer Inst 1995;87:796-802.
5. Ho GY, Bierman R, Beardsley L, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-8.
6. Schiffman MH, Bauer HM, Hoover RN, et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 1993;85:958-64.
7. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27.
8. Keating JT, Cviko A, Riethdorf S, et al. Ki-67, cyclin E, and p16INK4 are complementary surrogate biomarkers for human papillomavirus-related cervical neoplasia. Am J Surg Pathol 2001;25:884-91.
9. Bulten J, van der Laak JA, Gemmink JH, et al. MIB1, a promising marker for the classification of cervical intraepithelial neoplasia. J Pathol 1996;178:268-73.
10. Brown DC, Gatter KC. Ki-67 protein: the immaculate deception? Histopathology 2002;40:2-11.
11. Garzetti GG, Ciavatinni A, Lucarni G, et al. MIB1 immunostaining in stage I squamous cervical carcinoma: relationship with natural killer cell activity. Gynecol Oncol 1995;58:28-33.
12. Nakano T, Oka K. Differential values of Ki-67 index and mitotic index of proliferating cell population. An assessment of cell cycle and prognosis in radiation therapy for cervical cancer. Cancer 1993;72:2401-08.
13. Nanjyo T, Watanabe Y, Ikeda M. [The correlation between the therapeutic effects and tumor growth fraction in cervical cancer and ovarian cancer]. Nippon Sanka Fujinka Gakkai Zasshi 1994;46:27-34.
14. Nakano T, Oka K, Ishakawa A, et al. Correlation of cervical carcinoma c-erbB-2 oncogene with cell proliferation parameters in patients treated with radiation therapy for cervical carcinoma. Cancer 1997;79:513-20.
15. Ho DM, Hsu CY, Chiang H. MIB-1 labeling index as a prognostic indicator for survival in patients with FIGO stage IB squamous cell carcinoma of the cervix. Gynecol Oncol 2000;76:97-102.
16. Avall-Lundqvist EH, Silfversward C, Aspenblad U, et al. The impact of tumour angiogenesis, p53 overexpression and proliferative activity (MIB-1) on survival in squamous cervical carcinoma. Eur J Cancer 1997;33:1799-1804.
17. Dellas A, Moch H, Schultheiss E, et al. Angiogenesis in cervical neoplasia: microvessel quantitation in precancerous lesions and invasive carcinomas with clinicopathological correlation. Gynecol Oncol 1997;67:27-33.
18. Dellas A, Schultheiss E, Almendral AC, et al. Altered expression of mdm-2 and its association with p53 protein status, tumor-cell-proliferation rate and prognosis in cervical neoplasia. Int J Cancer 1997;74:421-5.
19. Oka K, Arai T. MIB1 growth fraction is not related to prognosis in cervical squamous cell carcinoma treated with radiotherapy. Int J Gynecol Pathol 1996;15:23-7.
20. Levine EL, Renehan A, Gossiel R, et al. Apoptosis, intrinsic radiosensitivity and prediction of radiotherapy response in cervical carcinoma. Radiother Oncol 1995;37:1-9.
21. Cole DJ, Brown DC, Crossley E, et al. Carcinoma of the cervix uteri: an assessment of the relationship of tumour proliferation to prognosis. Br J Cancer 1992;65:783-5.
22. Bulten J, de Wilde PC, Schijf C, et al. Decreased expression of Ki-67 in atrophic cervical epithelium of post-menopausal women. J Pathol 2000;190:545-53.
23. Zeng Z, Del PG, Cohen JM, et al. MIB-1 expression in cervical Papanicolaou tests correlates with dysplasia in subsequent cervical biopsies. Appl Immunohistochem Mol Morphol 2002;10:15-9.
24. Dunton CJ, Van Hoeven KH, Kovatich AJ, et al. Ki-67 antigen staining as an adjunct to identifying cervical intraepithelial neoplasia. Gynecol Oncol 1997;64:451-5.
25. Vassilakos P, Petignat P, Boulvain M, et al. Primary screening for cervical cancer precursors by the combined use of liquid-based cytology, computer-assisted cytology and HPV DNA testing. Br J Cancer 2002;86:382-8.
26. Sahebali S, Depuydt CE, Segers K, et al. Cervical cytological screening and HPV DNA testing in Flanders. Acta Clin Belg [In press.]
27. Depuydt CE, Vereecken AJ, Salembier GM et al. Thin-layer liquid-based cervical cytology and PCR for detecting and typing human papillomavirus DNA in Flemish women. Br J Cancer 2003;88:560-6.
28. Vassilakos P, Saurel J, Rondez R. Direct-to-vial use of the AutoCyte PREP liquid-based preparation for cervical-vaginal specimens in three European laboratories. Acta Cytol 1999;43:65-8.
29. Kurman RJ, Solomon D. The Bethesda system for reporting cervical/vaginal cytologic diagnoses. New York: Springer Verlag, 1994.
30. Bauer HM, Ting Y, Greer CE, et al. Genital human papillomavirus infection in female university students as determined by a PCR-based method. JAMA 1991;265:472-7.
31. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda system: terminology for reporting results of cervical cytology. JAMA 2002;287:2114-19.
32. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993;39:561-77.
33. Hanley JA, McNeill BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29-36.
34. Koss LG. The Papanicolaou test for cervical cancer detection. A triumph and a tragedy. JAMA 1989;261:737-43.
35. Clavel C, Masure M, Bory JP, et al. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer 2001;84:1616-23.
36. Karlsen F, Kalantari M, Jenkins A, et al. Use of multiple PCR primer sets for optimal detection of human papillomavirus. J Clin Microbiol 1996;34:2095-100.
37. Kulasingam SL, Hughes JP, Kiviat NB, et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity and frequency of referral. JAMA 2002;288:1749-57.
38. Ratnam S, Franco EL, Ferenczy A. Human papillomavirus testing for primary screening of cervical cancer precursors. Cancer Epidemiol Biomarkers Prev 2000;9:945-51.
39. Hong IS, Marshalleck J, Williams RH, et al. Comparative analysis of a liquid-based Pap test and concurrent HPV DNA assay of residual samples. A study of 608 cases. Acta Cytol 2002;46:828-34.